Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Receivables - Net (2021 - 2023)

Historic Receivables - Net for ADC Therapeutics (ADCT) over the last 3 years, with Q3 2023 value amounting to $21.2 million.

  • ADC Therapeutics' Receivables - Net fell 890.71% to $21.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was $21.2 million, marking a year-over-year decrease of 890.71%. This contributed to the annual value of $73.0 million for FY2022, which is 14148.19% up from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' Receivables - Net is $21.2 million, which was down 890.71% from $23.9 million recorded in Q2 2023.
  • Over the past 5 years, ADC Therapeutics' Receivables - Net peaked at $73.0 million during Q4 2022, and registered a low of $2079.0 during Q2 2021.
  • Its 3-year average for Receivables - Net is $21.6 million, with a median of $22.2 million in 2022.
  • As far as peak fluctuations go, ADC Therapeutics' Receivables - Net surged by 100341130.35% in 2022, and later crashed by 890.71% in 2023.
  • ADC Therapeutics' Receivables - Net (Quarter) stood at $30.2 million in 2021, then surged by 141.48% to $73.0 million in 2022, then plummeted by 70.97% to $21.2 million in 2023.
  • Its Receivables - Net stands at $21.2 million for Q3 2023, versus $23.9 million for Q2 2023 and $24.0 million for Q1 2023.